Pulmonx Q3 revenue beats analyst estimates on US sales growth
LUNG•Pulmonx's third-quarter revenue rose 6% year over year to $22.84 million, above the $21.94 million analyst estimate, as U.S. revenue grew 7%. The company maintained its 2026 revenue outlook of $90 million to $92 million and expects gross margin of about 77%.
1. Revenue and outlook
Pulmonx reported third-quarter revenue of $22.84 million, up 6% year over year and above the $21.94 million analyst estimate. U.S. revenue increased 7%; international revenue growth was limited by the lack of sales through a China distributor, while international revenue excluding China rose 9%.
2. Costs and 2026 targets
The company said cost realignment narrowed its adjusted EBITDA loss by 57% from a year earlier. Pulmonx maintained its 2026 revenue outlook of $90 million to $92 million, expects gross margin of about 77%, and forecasts operating expenses of $108 million to $109 million.
